Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski
Source: Daniel Levy, The Life Sciences Report  (4/8/15)
Cancers are generally treated by destruction of cancer cells. Infectious diseases are generally treated by destruction of invading pathogens. If infected host cells are viewed as viable biological targets, new paradigms for development of anti-infective agents become apparent. In this interview with The Life Sciences Report, Alexander Zukiwski MD, CEO and CMO of Arno Therapeutics Inc., describes how onapristone and AR-42 for cancers, and AR-12 as an anti-infective agent, are positioned to move through clinical trials and boost investors' portfolios. More >

Soligenix Takes the Fast Track to Beat Inflammation, Cancer and Bio-Threats: Dr. Christopher Schaber
Source: Daniel Levy, The Life Sciences Report  (4/8/15)
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin. More >

How Sunesis Pharmaceuticals Can Inhibit Cancer While Enhancing Investments: CEO Daniel Swisher
Source: Daniel Levy, The Life Sciences Report  (4/2/15)
Cancers are among today's most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis expects to hit the mark both for patients and investors. More >

With Expertise and a Little Luck, East West Petroleum Reels in Profits Despite Oil Price Plunge
Source: Kevin Michael Grace of The Energy Report  (3/26/15)
Many oil companies have been devastated by the oil price debacle. East West Petroleum, on the other hand, is making money, pumping more oil and strengthening its cash balance. CEO David Sidoo tells The Energy Report how shrewd joint ventures and a firm commitment to low costs have led to highly profitable wells in New Zealand and significant upside in Romania. More >

Galaxy Resources: A New Focus to Meet the Coming Lithium Demand
Source: Kevin Michael Grace  (3/5/15)
Just two years ago, Galaxy Resources was overleveraged and unfocused. It had lost the support of the market and its shareholders. Today, as Managing Director Anthony Tse explains in this interview with The Energy Report, a new management team has exerted fiscal discipline, consolidated assets and focused the company on its world-class Sal de Vida lithium project in Argentina, positioning Galaxy to supply a metal critical to the explosion in demand for modern electronics and transportation. More >

One Target with Multiple Shots on Goal: Can-Fite BioPharma CEO Pnina Fishman
  (3/4/15)
The target is a single receptor found only on abnormal cells—cancer cells and cells responsible for inflammatory diseases such as psoriasis. The weapon is a platform technology developed by Can-Fite BioPharma Ltd. under the guidance of Scientific Founder and CEO Pnina Fishman and her team. The company is developing an arsenal of therapies approaching the final stages of clinical trials, and in this interview with The Life Sciences Report, Fishman describes the catalysts and candidates that make Can-Fite a strong bet for investors. More >

Three for Three and Going for Four: Manitok Energy's Mass Geremia
Source: Kevin Michael Grace of The Energy Report  (2/26/15)
The oil price collapse has left most of the industry reeling, but Mass Geremia remains unbowed. The president and CEO of Alberta oil and gas company Manitok Energy Inc. used hedging to protect against the worst of the downturn. In this interview with The Energy Report, Geremia explains how his strategy of prudent and efficient "old school" expansion has Manitok on track to become an intermediate producer before the end of the decade. More >

CEL-SCI Corp.'s Novel Immunotherapies Set Sights on Cancer, Autoimmune Disorders and Infectious Diseases
Source: Dan Levy of The Life Sciences Report  (2/19/15)
Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited. That paradigm is changing, and CEL-SCI Corp. is among the companies poised to bring immunotherapy into these disease spaces. In this interview with The Life Sciences Report, Geert Kersten, CEL-SCI's CEO, describes how his company's Multikine and L.E.A.P.S. platforms can be deployed, and how investors can turn an immunotherapeutic win into profit. More >

Blackbird's Garth Braun: Leveraging Leadership, Foresight and Natural Gas Liquids
Source: George S. Mack of The Energy Report  (2/10/15)
When an energy company has grown its share price more than 400% against strong headwinds in one year, that's an attention-getter. The formula, as always, is to get the right management, after which value will be created and growth will follow. CEO Garth Braun of Blackbird Energy Inc. has made sweet lemonade out of a sour market in fossil fuels. In this interview with The Energy Report, Braun describes his business model and talks about his management and leadership style. More >

The Diabetes Economy: Miraculins Scouts for Worldwide Markets
Source: Taylor Thoen, BTV/The Life Sciences Report   (2/4/15)
While other diseases catch headlines and media attention, diabetes has crept quietly into a full-blown, worldwide pandemic. With the Scout DS^®, Winnipeg-based Miraculins Inc. is on the leading edge of medical innovation with the world's first noninvasive retail screening test for diabetes. In this interview with The Life Sciences Report, Miraculins President and CEO Christopher Moreau explains how the company is poised to expand into multiple markets to meet a desperate need for diabetes screening in North America and around the world. More >

The Outpatient Surgery Business Rains Cash: Nobilis Health's Harry Fleming
Source: Peter Byrne of The Life Sciences Report  (1/22/15)
Nobilis Health Corp. has invented a genuine recipe for success: Provide outpatient surgical services with high profit margins and saturate a local consumer health market with advertising. In this interview with The Life Sciences Report, Nobilis' president Harry Fleming explains exactly how his booming firm's business model works—and why investors should take note of the new kid on the block. More >

Geology and Logistics Make the Bayovar 12 Phosphate Project Tough to Beat
Source: Brian Sylvester of The Mining Report  (1/15/15)
The planet's population is growing by 60 million each year. More crops on less land will mean farmers will have to use more fertilizer, and that's an investment thesis worthy of a closer look. Savvy investors will want to take a look at phosphate, a key element in fertilizer, and the companies that mine it. Focus Ventures Ltd. is earning a 70% stake in a phosphate project in Peru that should be a low-cost producer for decades to come. In this interview with The Mining Report, Focus President and Director David Cass and Vice President of Corporate Development Ralph Rushton discuss some the finer points of the phosphate market and their flagship Bayovar 12 project. More >

Radisson Mining Believes Small Is Beautiful, For Now
Source: Brian Sylvester of The Gold Report  (1/12/15)
It is good to know what you are and what you are not. Radisson Mining Resources Inc. knows what it is—a small gold exploration company with aims of becoming a small gold producer inside 28 months. Radisson Mining President and CEO Mario Bouchard believes his company has a realistic plan in place to reach its goal and it's just a matter of focus and execution. Bouchard explains his plan and his company's identity in this interview with The Gold Report.
More >

The Copper Denominator: Gianni Kovacevic
Source: J. Alec Gimurtu of The Gold Report  (12/15/14)
Gianni Kovacevic, the author of "My Electrician Drives a Porsche?" and executive chairman of CopperBank Resources Corp., takes a scientific view of historical, social and environmental trends in energy usage and identifies copper as the common denominator. As global energy usage increases, most of that energy flows through copper. In this interview with The Gold Report, Kovacevic discusses how his book explains his approach in understanding copper's investment opportunity in a scientific context, and the role of the company he founded to take advantage of this secular trend. More >

Taking Multiple Shots on the Cancer Treatment Goal: Rexahn's Peter Suzdak
Source: George S. Mack of The Life Sciences Report  (11/28/14)
Rexahn Pharmaceuticals Inc.'s cancer-fighting drug development platform is built on a theme that focuses on targets exclusive to tumor cells—the ultimate strategy in the silver-bullet theory of dealing with disease because it can increase efficacy while reducing off-target effects, including heart and liver toxicity. Moreover, lower toxicity enables higher drug doses, which could enhance the desired therapeutic effects. In this interview with The Life Sciences Report, Rexahn CEO Peter D. Suzdak, Ph.D. talks about his company's clinical-stage drug candidates, and links their mechanisms of action to the ultimate value proposition for owning company shares. More >

UEX's Lemaitre Talks Blue Chip Junior Strategy: Exploration Excellence
Source: Kevin Michael Grace of The Energy Report  (11/13/14)
After losing half of its value, the spot price of uranium has in recent weeks risen from less than $30 per pound to $42 per pound. Roger Lemaitre, President and CEO of UEX Corp., is pleased but not surprised, as a supply shortage looms, and sanctions against Russia are spooking utilities. In this interview with The Energy Report,
Lemaitre explains how its substantial resources in Saskatchewan's Athabasca Basin have primed UEX to move forward when uranium prices rise to meet demand. More >

R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy
Source: George S. Mack of The Life Sciences Report  (11/6/14)
Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications. RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) is tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin. In this interview with The Life Sciences Report, R. Lee Buckler, the company's new vice president of business and corporate development, discusses his firm's innovative technology platform and the upcoming milestones that could affect its shares. More >

The Game-Changing Potential of DNA Vaccines: Inovio's Dr. Joseph Kim
Source: George S. Mack of The Life Sciences Report  (10/29/14)
Since Edward Jenner's development of the smallpox vaccine in the late 1790s, humankind has enjoyed the benefit of immunization, which has saved many millions of lives. Today, Inovio Pharmaceuticals Inc. (INO:NASDAQ) is in the forefront of developing DNA vaccines, inserting engineered genes into cellular machinery to synthesize proteins that, in turn, generate antibodies that fight disease. An additional benefit is a powerful T-cell response, which harnesses the patient's own capacity to fight infections and cancers. If pivotal studies read out favorably, DNA immunization could prove a true game changer in healthcare. In this interview with The Life Sciences Report, Inovio President and CEO J. Joseph Kim discusses his company's platform technology, which addresses both therapeutic and preventive methods of fighting disease. More >

Follow the Baby Boom to Profits: Agility Health's Steven Davidson
Source: Peter Byrne of The Life Sciences Report  (10/21/14)
In recent years, entrepreneurial therapists have comprised the fast-growing sector in outpatient physical therapy. But companies like Agility Health are beginning to seize acquisition opportunities and market share in this growing sector. Steven Davidson, CEO of Agility Health Inc., tells The Life Sciences Report how his company is innovating in the physical therapy space, improving patient care and clients' bottom lines through its management expertise and proprietary software, AgileRPM. With baby boomers aging and the Affordable Care Act increasing access to services, physical therapy just might be the safe haven sector to shield your portfolio from macroeconomic uncertainty. More >

Dial In on Diabetes Solutions with LabStyle Innovations Corp.'s Dario
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (7/17/14)
Having a chronic disease like diabetes engenders a sense of isolation that hasn't been adequately addressed by technology until now. With Dario, LabStyle Innovations Corp. has created a device that not only provides vital medical information to a diabetic patient in real time, but also connects that patient to a community of care providers, family and online resources. In this interview with The Life Sciences Report, LabStyle President and CEO Erez Raphael describes how the Dario software platform could provide sufferers of other chronic diseases with the benefits of real-time data and community as well. More >

Balmoral Resources: Two Projects, One Vision, Proven Share Price Performance
Source: Taylor Thoen, BTV/The Gold Report   (6/18/14)
With two 100%-owned, shallow, high-grade properties in Canada churning out results and millions of dollars in the bank to keep the drills turning, Balmoral Resources is taking advantage of elevated nickel prices and a quiet junior mining backdrop to turn investors' heads. President and CEO Darin Wagner shares his focus for moving both projects forward. More >

Gold Standard Ventures Consolidates Southern Carlin Trend District
Source: J. Alec Gimurtu of The Gold Report  (5/21/14)
All serious gold investors know the Carlin Trend of Nevada is one of the most prolific gold producing regions of the world. Is it possible that there is an undiscovered district, not just a deposit, within that region that was missed by the majors? Jon Awde, CEO of Gold Standard Ventures, discusses how spectacular drill results have guided Gold Standard Ventures to focus on creating the southernmost mining district of the Carlin Trend—the Railroad/Pinion District. At more than 40 square miles, the district is large enough to potentially sustain a mid-sized producer. In this interview with The Gold Report, Awde describes the unique challenges of proving up a series of deposits that are in the shadow of the majors and for the first time all combined under one company in a single mining district. More >

Novel Tools for Early Cancer Detection: Verisante Technology Inc.
Source: Daniel Levy of The Life Sciences Report  (4/17/14)
Early detection of cancer has a profound impact on the effectiveness of medical/surgical treatments, as well as on the long-term prognoses of patients. Consequently, new technologies are evolving with the ability to detect cancers in their earliest and most treatable stages. In this interview with The Life Sciences Report, Thomas Braun, president and CEO of Verisante Technology Inc., describes his company's Aura and Core devices, and their utility in early cancer detection. More >

Gener8 Disrupts the Big Data Status Quo
Source: Peter Byrne of Streetwise Reports' Special Situations  (4/16/14)
Big data is taking over the world, and Rory Armes and Ken Scott of Gener8 Media Corp. know why. In this interview with Streetwise Reports' Special Situations, the two Vancouver-based upstarts discuss the tribulations of getting in on the ground floor of the newest developments in information technology—and the many potential rewards. More >

Royal Nickel Corp: Indonesian Ore Export Ban Opens Door to the Next Generation of Nickel Mines
Source: J. Alec Gimurtu of The Mining Report  (2/11/14)
Nickel prices have been weak, but the recent Indonesian government announcement banning ore shipments outside the country may be the shock that reverses the trend. In this interview with The Mining Report, Mark Selby, Interim CEO of Royal Nickel Corp., walks through his analysis that indicates nickel price increases and inventory reductions are imminent, while demand continues to grow and over a quarter of global mine supply is shut in. He considers nickel in 2014 one of the best commodity trades in a generation. To capitalize on this unique set of circumstances, Royal Nickel's Dumont Nickel Project follows the path of other large-reserve, large-scale mines in the copper and gold sectors that have changed the mining industry and made early investors fortunes. More >